IZOZF Stock Price & Financials - Izotropic Corporation
$0.19 (-1.55%)| freeCashFlowPerShare | -0.066 |
| marketCap | 16,959,212.744 |
| peRatio | -2.996 |
| freeCashFlowYield | -0.195 |
| payoutRatio | 0 |
| roic | 6.01 |
| Price | 0.066 |
| VolAvg | 17,129 |
| MktCap | 3,629,756 |
| LastDiv | 0 |
| industry | Medical - Diagnostics & Research |
Income Statement Financials
Balance Statement Financials
Cash Flow Statement Financials
| 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | |
|---|---|---|---|---|
| fillingDate | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 |
| calendarYear | 2,023 | 2,022 | 2,021 | 2,020 |
| period | FY | FY | FY | FY |
| cashAndCashEquivalents | 165,685 | 1,856,573 | 4,063,756 | 613,572 |
| shortTermInvestments | 28,750 | 0 | 0 | 0 |
| cashAndShortTermInvestments | 165,685 | 1,856,573 | 4,063,756 | 613,572 |
| netReceivables | 13,406 | 41,261 | 43,894 | 47,207 |
| inventory | 0 | 0 | 0 | 0 |
| otherCurrentAssets | 138,253 | 352,214 | 577,374 | 113,171 |
| totalCurrentAssets | 317,344 | 2,250,048 | 4,685,024 | 773,950 |
| propertyPlantEquipmentNet | 124,769 | 18,987 | 1,631 | 3,261 |
| goodwill | 0 | 0 | 0 | 0 |
| intangibleAssets | 0 | 0 | 0 | 0 |
| goodwillAndIntangibleAssets | 0 | 0 | 0 | 0 |
| longTermInvestments | 0 | 0 | 0 | 0 |
| taxAssets | 0 | 0 | 0 | 0 |
| otherNonCurrentAssets | 0 | 0 | 0 | 0 |
| totalNonCurrentAssets | 124,769 | 18,987 | 1,631 | 3,261 |
| otherAssets | 0 | 0 | 0 | 0 |
| totalAssets | 442,113 | 2,269,035 | 4,686,655 | 777,211 |
| accountPayables | 1,145,942 | 378,011 | 94,666 | 61,492 |
| shortTermDebt | 2,083,223 | 2,028,154 | 0 | 0 |
| taxPayables | 0 | 0 | 0 | 0 |
| deferredRevenue | 0 | 0 | 0 | 0 |
| otherCurrentLiabilities | 231,006 | 237,459 | 74,616 | 8,500 |
| totalCurrentLiabilities | 3,460,171 | 2,643,624 | 169,282 | 69,992 |
| longTermDebt | 55,701 | 0 | 0 | 0 |
| deferredRevenueNonCurrent | 0 | 0 | 0 | 0 |
| deferrredTaxLiabilitiesNonCurrent | 0 | 0 | 0 | 0 |
| otherNonCurrentLiabilities | 0 | 0 | 0 | 0 |
| totalNonCurrentLiabilities | 55,701 | 0 | 0 | 0 |
| otherLiabilities | 0 | 0 | 0 | 0 |
| totalLiabilities | 3,515,872 | 2,643,624 | 169,282 | 69,992 |
| preferredStock | 0 | 0 | 0 | 0 |
| commonStock | 13,353,439 | 11,278,117 | 10,041,597 | 2,729,503 |
| retainedEarnings | -18,092,050 | -13,979,997 | -7,325,305 | -2,349,179 |
| accumulatedOtherComprehensiveIncomeLoss | -822 | 2,327,291 | 1,801,081 | 326,895 |
| othertotalStockholdersEquity | 1,665,674 | 0 | 0 | 0 |
| totalStockholdersEquity | -3,073,759 | -374,589 | 4,517,373 | 707,219 |
| totalLiabilitiesAndStockholdersEquity | 442,113 | 2,269,035 | 4,686,655 | 777,211 |
| totalInvestments | 28,750 | 0 | 0 | 0 |
| totalDebt | 2,138,924 | 2,028,154 | 0 | 0 |
| netDebt | 1,973,239 | 171,581 | -4,063,756 | -613,572 |
| link | ||||
| finalLink | ||||
| minorityInterest | 0 | 0 | 0 | 0 |
| capitalLeaseObligations | 88,924 | 0 | 0 | 0 |
| totalEquity | -3,073,759 | -374,589 | 4,517,373 | 707,219 |
Izotropic Corporation
Description: Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Website:https://izocorp.com
Industry: Medical - Diagnostics & Research
Sector: Healthcare
CEO:
Full-Time Employees:
Address: 800 – 15355 24th Avenue, Surrey, BC, V4A 2H9, CA
Phone: 833 496 2677
Currency: USD
CIK:
ISIN: CA46604F1099
CUSIP:
Exchange: Other OTC
Exchange Short Name: PNK
IPO Date: 2021-01-08
| Ticker | peRatio | enterpriseValueOverEBITDA | evToFreeCashFlow | roic | netCurrentAssetValue | bookValuePerShare | priceToSalesRatio | netIncomePerShare |
|---|---|---|---|---|---|---|---|---|
| IZOZF | -3.00 | -3.57 | 6.01 | -3,198,528.00 | -0.06 | 0.00 | -0.11 | |
| IVRO | 838.98 | -47.11 | -0.01 | 1,388,183.00 | 0.06 | 1.64 | 0.00 | |
| BDSX | -2.90 | -5.18 | -1.14 | -54,833,000.00 | 0.06 | 3.08 | -0.64 | |
| STIM | -2.75 | -3.01 | -0.32 | 12,152,000.00 | 1.19 | 1.16 | -1.05 | |
| STRR | -52.83 | -46.34 | -0.04 | 13,131,000.00 | 4.18 | 1.79 | -0.10 | |
| GTH | ||||||||
| PMD | -4.09 | -69.02 | -0.39 | 207,000.00 | 1.16 | 0.77 | -0.72 | |
| SERA | -5.15 | -4.78 | -0.56 | 36,061,000.00 | 2.25 | 609.74 | -1.16 | |
| OLK | -98.51 | -97.86 | -0.07 | 163,916,107.00 | 4.05 | 18.35 | -0.26 | |
| DRIO | -0.89 | -0.81 | -0.65 | 8,847,000.00 | 2.05 | 2.40 | -1.93 | |
| RSHN | -2.83 | -10.24 | -0.12 | -5,757,902.00 | 0.00 | 0.96 | 0.00 | |
| APDN | -1.59 | -0.95 | -1.76 | -652,595.00 | 7.57 | 1.18 | -15.21 | |
| AKU | ||||||||
| RDNT | 726.24 | 11.89 | 0.05 | -1,494,057,999.00 | 9.92 | 1.37 | 0.05 | |
| STRRP | -52.83 | -46.34 | -0.04 | 13,131,000.00 | 4.18 | 1.79 | -0.10 | |
| LAB | -2.34 | -4.63 | -0.27 | -1,650,000.00 | 2.06 | 1.65 | -0.94 | |
| NDRA | -1.34 | -1.08 | -1.74 | 1,937,655.00 | 0.89 | 0.00 | -1.58 |
Analyst Estimates
Latest News
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has engaged an International Communications Consultant, and granted Incentive Stock Options and Restricted Share Units to Directors, Advisors, and Key Consultants. International Communications Consultant Izotropic has engaged JG Global Communications, led by Mr.
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
- FDA meeting facilitated positive collaborative exchange - - Key topics included the clinical study protocol synopsis, the benefits versus risks of contrast-enhancement, and the management of breast cancers found on IzoView Breast CT that are not visible on digital breast tomosynthesis - - Izotropic to submit meeting minutes to the FDA prior to more detailed disclosure - Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 25, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that it completed its pre-submission meeting with the U.S. Food and Drug Administration ("FDA") as scheduled on March 20, 2025. The purpose of the meeting was to discuss Izotropic's recent pre-submission filing and advance the regulatory strategy for its IzoView Breast CT Imaging System.
Izotropic to Present at Investor Conference March 13th
- CEO to discuss IzoView's competitive advantage, expansion strategy, and potential revenue models - - Event includes live Q and A, attendance is complimentary - - Individual and institutional investors, advisors, and analysts welcome - Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that CEO Robert Thast will be presenting at the Life Sciences Virtual Investor Conference this week, where he will highlight the transformative potential of the Company's first medical imaging device, the IzoView Breast CT system, in the expanding breast imaging market. Date: March 13th, 2025 Time: 11:00 - 11:30am PST / 2:00 - 2:30pm EST Book a 1 x 1 Meeting: See availability here: https://calendly.com/izotropic/meeting-with-ceo The global breast imaging device market is expected to surge from $5.40 billion in 2024 to $8.69 billion by 2030, driven by rising breast cancer incidence rates, aging populations, and expanding adoption in emerging markets.
FDA Sets Meeting Date with Izotropic
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that the U.S. Food and Drug Administration ("FDA") has set the Company's pre-submission meeting date, further to its January pre-submission filing. The Company filed a pre-submission with the FDA on the subject of its clinical study design for the approval of its first medical imaging device, the IzoView Breast CT Imaging System ("IzoView").
Izotropic Closes Non-Brokered Private Placement
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 14, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its February 7th announcement it has completed a non-brokered private placement financing (the "Offering"), whereby the Company issued 3,033,333 units (each, a "Unit") at a price of $0.15 per Unit for gross proceeds of $455,000. Each Unit consists of one common share and one transferable warrant (each, a "Warrant"), and each Warrant entitles the holder to purchase one additional share at a price of $0.30 per share for a period of two (2) years from closing of the Offering.
Izotropic Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 7, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up to 2,400,000 units of the Company, (each a "Unit") at a price of $0.15 per each Unit for a gross proceeds of up to $360,000.00. Each Unit will consist of one common share and one transferable Warrant (each, a "Warrant"), and each Warrant will entitle the holder to purchase one additional share at a price of $0.30 per share for a period of two (2) years from the closing of the Offering.
